Testosterone-SAG Combination for Remyelination in Demyelinating Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for demyelinating diseases, such as multiple sclerosis, are ineffective in progressive forms and often associated with significant side effects, and there is a need for methods that promote remyelination effectively.
Innovation Solution
Administering a steroid hormone, specifically testosterone, in combination with a Hedgehog signaling pathway modulator, such as the Smoothened agonist SAG, to synergistically enhance the production of oligodendrocytes and myelin-producing cells, promoting remyelination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (immunomodulators) are used to treat progressive forms of multiple sclerosis, then some effectiveness is achieved, but major side effects occur and tolerance is poor
Solution Approach 1:
The patent changes the therapeutic approach by shifting from immunomodulation to remyelination promotion through Hedgehog pathway activation and steroid hormone administration, fundamentally altering the mechanism of action to achieve effectiveness in progressive forms without the harmful side effects of current immunomodulators
Solution Approach 2:
The patent converts the harmful effect of demyelination into a beneficial process by activating endogenous remyelination mechanisms through Hedgehog pathway modulation, transforming the disease state into a regenerative opportunity
2Ease of operation
If current treatments are used to improve function after attacks, then symptom management is achieved, but new attacks continue to occur
Solution Approach 1:
The patent applies preliminary action by promoting remyelination before new demyelinating attacks occur, creating a protective myelin layer that prevents future attacks and improves functional outcomes before disease progression can manifest
3Reliability
If immunomodulators are used to prevent new attacks, then attack prevention is achieved, but the treatments are expensive and have significant side effects
Solution Approach 1:
The patent enables self-service by activating the body's own remyelination capabilities through Hedgehog pathway modulation and steroid hormone administration, eliminating the need for expensive immunomodulators and their associated side effects while maintaining attack prevention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy significantly increases the number of oligodendrocytes and myelin-producing cells, leading to improved remyelination and more effective treatment of demyelinating diseases, including multiple sclerosis.
Implementation Method 1
The Hedgehog signaling pathway modulator is the Smoothened (Smo) agonist 3-Chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[[3-(4-pyridinyl)phenyl]methyl]benzo[b]thiophene-2-carboxamide (SAG)
Implementation Method 2
The steroid hormone is the androgen receptor ligand testosterone
Data Source
Figure 1A~1D
Figure 2A~2B
Figure 3A~3D
AI summary
Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.